Victrex (LON:VCT) was downgraded by investment analysts at Morgan Stanley to an “underweight” rating in a research report issued on Friday, October 12th. They presently have a GBX 2,300 ($30.05) target price on the stock, down from their previous target price of GBX 2,500 ($32.67). Morgan Stanley’s target price would indicate a potential downside of 15.00% from the stock’s current price.
A number of other research analysts have also commented on VCT. Citigroup reissued a “neutral” rating on shares of Victrex in a report on Tuesday, July 17th. Barclays reissued an “underweight” rating and set a GBX 2,380 ($31.10) price target (up from GBX 2,300 ($30.05)) on shares of Victrex in a report on Tuesday, July 24th. Liberum Capital reaffirmed a “buy” rating and set a GBX 2,825 ($36.91) target price on shares of Victrex in a research note on Wednesday, July 25th. Peel Hunt reaffirmed an “add” rating on shares of Victrex in a research note on Wednesday, July 25th. Finally, UBS Group reaffirmed a “buy” rating and set a GBX 3,600 ($47.04) target price (up previously from GBX 3,300 ($43.12)) on shares of Victrex in a research note on Thursday, October 4th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of GBX 2,560.45 ($33.46).
Shares of VCT traded down GBX 14 ($0.18) during trading hours on Friday, reaching GBX 2,706 ($35.36). 183,640 shares of the company’s stock traded hands, compared to its average volume of 274,177. Victrex has a twelve month low of GBX 1,826 ($23.86) and a twelve month high of GBX 2,772 ($36.22).
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
See Also: Preferred Stock
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.